Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Margo Block

Neurology Independence, MO Doctor of Osteopathy

NPI 1871672287 CMS profile 358075

19550 E 39Th St S, Suite 105A, Independence, MO 64057

Open in the dashboard

General payments

$164,424

108 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Margo Block of Independence, MO is reported in the CMS Open Payments database as having received $164,424 across 108 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $935 3
2024 General $120,783 11
2023 General $35,004 15
2022 General $6,766 23
2021 General $316 19
2020 General $191 16
2019 General $429 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Margo Block
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Margo Block were reported at $935. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Margo Block Neurology median Middle half National median
2019 $429 $474 $118–$2,177 $163
2020 $191 $367 $82–$2,309 $114
2021 $316 $438 $104–$2,547 $132
2022 $6,766 $442 $103–$2,388 $149
2023 $35,004 $464 $119–$2,312 $160
2024 $120,783 $468 $119–$2,323 $164
2025 $935 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ceribell, Inc. $162,701 16 payments
  2. AbbVie, Inc. $283 17 payments
  3. UCB, Inc. $186 9 payments
  4. Allergan Inc. $173 15 payments
  5. Lundbeck LLC $171 8 payments
  6. Amgen Inc. $123 5 payments
  7. Teva Pharmaceuticals USA, Inc. $97 6 payments
  8. LivaNova USA, Inc. $84 2 payments
  9. Jazz Pharmaceuticals Inc. $82 4 payments
  10. Argenx US, Inc. $60 2 payments
  11. Other $463 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $162,632 14 payments
  2. Food and Beverage $1,763 93 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $29 1 payment
Products named General payments · program years 2019–2025
  1. POCKET EEG DEVICE $121,683 13 payments
  2. Ceriell Rapid Response EEG $34,700 1 payment
  3. Ceribell Rapid Response EEG $6,300 1 payment
  4. UBRELVY Neuroscience $174 11 payments
  5. AIMOVIG $152 7 payments
  6. Briviact $131 7 payments
  7. UBRELVY Neuroscience $102 10 payments
  8. BOTOX $81 5 payments
  9. VYEPTI $70 3 payments
  10. VNS Therapy $67 1 payment
  11. Other $941 48 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

576

Median for Neurology: 833

Drug cost

$48,661

Median for Neurology: $202,670

Branded share of claims

8.3%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Briviact Brivaracetam Brand 14 $25,190
Levetiracetam Generic 160 $6,299
Lacosamide Generic 32 $4,722
Carbamazepine Generic 21 $2,354
Oxcarbazepine Generic 33 $2,279
Zonisamide Generic 48 $1,410
Carbidopa-Levodopa Carbidopa/Levodopa Brand 17 $1,100
Divalproex Sodium Generic 11 $1,071
Divalproex Sodium Er Divalproex Sodium Brand 17 $946
Sumatriptan Succinate Generic 11 $927

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$9,765

Medicare's payments for the services billed

Medicare patients

51

Average age 71

Services billed

160

25 women, 26 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Chronic kidney disease 55%
Depression 51%
Diabetes 49%
Ischemic heart disease 45%
Heart failure 29%
Atrial fibrillation 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

108 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record